Biologics
Total Trials
32
As Lead Sponsor
21
As Collaborator
11
Total Enrollment
3,171
NCT05129644
Single Dose Escalation Study of P1101 in Healthy Adult Male Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 7, 2009
Completion: Jun 26, 2010
NCT01587586
Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection
Phase: Phase 2
Start: Oct 18, 2011
Completion: Nov 22, 2016
NCT04035473
A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
Role: Collaborator
Start: Aug 1, 2015
Completion: Mar 27, 2019
NCT04180384
A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients
Start: Sep 23, 2015
Completion: Jun 15, 2021
NCT05522816
KX01 Ointment Phase 1 Study in Patients With Plaque Type Psoriasis
Start: Oct 27, 2015
Completion: Mar 10, 2021
NCT04382937
Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection
Phase: Phase 3
Start: Jan 12, 2016
Completion: Jul 15, 2020
NCT03165955
A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
Start: May 9, 2017
Completion: Nov 22, 2018
NCT04168957
An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007
Start: Oct 25, 2017
Completion: Nov 12, 2020
NCT03546465
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects
Start: May 7, 2018
Completion: Jul 15, 2019
NCT04233840
P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma
Phase: Phase 1/2
Start: Feb 12, 2019
Completion: Jul 31, 2023
NCT04182100
Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply
Start: Dec 20, 2019
Completion: Mar 8, 2021
NCT04285086
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
Start: Aug 25, 2020
Completion: Aug 31, 2029
NCT04774107
The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
Start: Nov 26, 2020
Completion: Jul 18, 2022
NCT04655092
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Start: Jan 19, 2021
Completion: Jun 30, 2026
NCT05494528
Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy
Phase: N/A
Start: May 4, 2021
Completion: Dec 30, 2024
NCT05485948
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
Start: Oct 8, 2021
Completion: Jul 31, 2027
NCT05245578
Safety Evaluation of KX01 Ointment 1% in Japanese Healthy Male Subjects
Start: Nov 16, 2021
Completion: Jan 12, 2022
NCT05231044
A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp
Start: Dec 21, 2021
Completion: Nov 20, 2023
NCT04638439
The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
Start: Aug 17, 2022
Completion: May 14, 2025
NCT05482971
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Start: Sep 29, 2022
Completion: Mar 31, 2027
NCT05481151
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
Start: Oct 26, 2022
NCT05467553
A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection
Start: Feb 24, 2023
Completion: Aug 31, 2025
NCT06665776
HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan
Start: Mar 14, 2023
Completion: Dec 31, 2025
NCT06002490
A Study to Evaluate P1101 in Japanese PV Patients
Start: Oct 17, 2023
Completion: Jul 26, 2024
NCT06698861
A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers
Start: Aug 19, 2024
Completion: Feb 6, 2025
NCT07053904
Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors
Start: Apr 21, 2025
Completion: Dec 31, 2029
NCT06468033
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
Start: Jul 18, 2025
Completion: Sep 30, 2028
NCT07047885
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
Start: Aug 27, 2025
Completion: Jun 30, 2028
NCT06290765
Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera
Phase: Phase 4
Start: Feb 1, 2026
Completion: Jun 30, 2027
Loading map...